Beth Borowsky

4.6k total citations · 3 hit papers
35 papers, 2.7k citations indexed

About

Beth Borowsky is a scholar working on Cellular and Molecular Neuroscience, Neurology and Molecular Biology. According to data from OpenAlex, Beth Borowsky has authored 35 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Cellular and Molecular Neuroscience, 21 papers in Neurology and 12 papers in Molecular Biology. Recurrent topics in Beth Borowsky's work include Genetic Neurodegenerative Diseases (28 papers), Neurological disorders and treatments (20 papers) and Mitochondrial Function and Pathology (9 papers). Beth Borowsky is often cited by papers focused on Genetic Neurodegenerative Diseases (28 papers), Neurological disorders and treatments (20 papers) and Mitochondrial Function and Pathology (9 papers). Beth Borowsky collaborates with scholars based in United States, United Kingdom and Canada. Beth Borowsky's co-authors include Julie C. Stout, Sarah J. Tabrizi, Ralf Reilmann, Blair R. Leavitt, Alexandra Dürr, Raymund A.C. Roos, Rachael I. Scahill, G. Bernhard Landwehrmeyer, Hans J. Johnson and David Craufurd and has published in prestigious journals such as PLoS ONE, Neurology and Annals of Neurology.

In The Last Decade

Beth Borowsky

35 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data

2009 756 citations Sarah J. Tabrizi, Douglas R. Langbehn et al. The Lancet Neurology profile →
Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data

2013 622 citations Sarah J. Tabrizi, Rachael I. Scahill et al. The Lancet Neurology profile →
A biological classification of Huntington's disease: the Integrated Staging System

2022 142 citations Sarah J. Tabrizi, Scott Schobel et al. The Lancet Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Beth Borowsky United States	17	2.3k	1.8k	1.2k	298	211	35	2.7k
Andrew Churchyard Australia	33	1.9k 0.8×	1.8k 1.0×	978 0.8×	389 1.3×	304 1.4×	89	2.8k
Luis Velázquez‐Pérez Cuba	27	1.6k 0.7×	959 0.5×	1.3k 1.1×	123 0.4×	49 0.2×	110	2.1k
Liliana Menalled United States	19	2.0k 0.8×	1.0k 0.5×	1.5k 1.2×	128 0.4×	42 0.2×	28	2.3k
Jean‐Luc Houéto France	28	1.5k 0.6×	2.7k 1.5×	172 0.1×	367 1.2×	69 0.3×	51	3.2k
Colin Deransart France	21	1.7k 0.7×	687 0.4×	402 0.3×	1.2k 4.1×	208 1.0×	31	2.4k
Véronique M. André United States	21	1.8k 0.7×	804 0.4×	962 0.8×	241 0.8×	18 0.1×	26	2.0k
Joshua A. Goldberg Israel	27	2.3k 1.0×	1.6k 0.9×	816 0.7×	992 3.3×	35 0.2×	47	3.1k
Giuseppe Sciamanna Italy	25	1.4k 0.6×	1.1k 0.6×	485 0.4×	266 0.9×	22 0.1×	49	1.8k
Jorge Flores‐Hernández Mexico	22	1.5k 0.7×	412 0.2×	951 0.8×	394 1.3×	25 0.1×	43	2.0k
Pascal Salin France	30	1.6k 0.7×	1.1k 0.6×	642 0.5×	232 0.8×	22 0.1×	83	2.2k

Countries citing papers authored by Beth Borowsky

Since Specialization

Citations

This map shows the geographic impact of Beth Borowsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beth Borowsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beth Borowsky more than expected).

Fields of papers citing papers by Beth Borowsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beth Borowsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beth Borowsky. The network helps show where Beth Borowsky may publish in the future.

Co-authorship network of co-authors of Beth Borowsky

This figure shows the co-authorship network connecting the top 25 collaborators of Beth Borowsky. A scholar is included among the top collaborators of Beth Borowsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beth Borowsky. Beth Borowsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tariot, Pierre N., Marie‐Emmanuelle Riviere, Stephen Salloway, et al.. (2024). Reversibility of cognitive worsening observed with BACE inhibitor umibecestat in the Alzheimer's Prevention Initiative (API) Generation Studies. Alzheimer s & Dementia. 20(11). 7745–7761. 6 indexed citations

Roussakis, Andreas–Antonios, Mark Forrest Gordon, Ralf Reilmann, et al.. (2023). A PET-CT study on neuroinflammation in Huntington’s disease patients participating in a randomized trial with laquinimod. Brain Communications. 5(2). fcad084–fcad084. 13 indexed citations

Tabrizi, Sarah J., Scott Schobel, Emily C. Gantman, et al.. (2022). A biological classification of Huntington's disease: the Integrated Staging System. The Lancet Neurology. 21(7). 632–644. 142 indexed citations breakdown →

Tabrizi, Sarah J., Scott Schobel, Emily C. Gantman, et al.. (2021). F01 Development of the huntington’s disease integrated staging system (HD-ISS). A19.2–A20. 2 indexed citations

Tariot, Pierre N., Beth Borowsky, Fonda Liu, et al.. (2020). The Generation program: Baseline characteristics of cognitively unimpaired APOE4 carriers recruited for Generation study 1 and Generation study 2. Alzheimer s & Dementia. 16(S9). 2 indexed citations

D, Juan F. Domínguez, Govinda Poudel, Julie C. Stout, et al.. (2017). Longitudinal changes in the fronto-striatal network are associated with executive dysfunction and behavioral dysregulation in Huntington's disease: 30 months IMAGE-HD data. Cortex. 92. 139–149. 24 indexed citations

Kieburtz, Karl, G. Bernhard Landwehrmeyer, Ralf Reilmann, et al.. (2017). Efficacy, Safety, and Tolerability of Pridopidine in Huntington Disease (HD): Results from the Phase II, Double-blind, Placebo-controlled, Dose-Ranging Study, Pride-HD (P2.005). Neurology. 88(16_supplement). 10 indexed citations

Wiecki, Thomas V., Chrystalina A. Antoniades, Christopher Kennard, et al.. (2016). A Computational Cognitive Biomarker for Early-Stage Huntington’s Disease. PLoS ONE. 11(2). e0148409–e0148409. 34 indexed citations

Labuschagne, Izelle, Amy Mulick, Rachael I. Scahill, et al.. (2016). Visuospatial Processing Deficits Linked to Posterior Brain Regions in Premanifest and Early Stage Huntington’s Disease. Journal of the International Neuropsychological Society. 22(6). 595–608. 42 indexed citations

10.

Klöppel, Stefan, Sarah Gregory, Elisa Scheller, et al.. (2015). Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study. EBioMedicine. 2(10). 1420–1429. 101 indexed citations

11.

Lázár, Alpár S., Francesca Panin, Anna Goodman, et al.. (2015). Sleep, But No Metabolic, Deficits In Pre-Manifest Huntington's Disease. 3 indexed citations

12.

Poudel, Govinda, Julie C. Stout, Juan F. Domínguez D, et al.. (2013). Functional changes during working memory in Huntington’s disease: 30-month longitudinal data from the IMAGE-HD study. Brain Structure and Function. 220(1). 501–512. 52 indexed citations

13.

Tabrizi, Sarah J., Rachael I. Scahill, Gail Owen, et al.. (2013). Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. The Lancet Neurology. 12(7). 637–649. 622 indexed citations breakdown →

14.

Georgiou‐Karistianis, Nellie, Govinda Poudel, Juan F. Domínguez D, et al.. (2013). Functional and connectivity changes during working memory in Huntington’s disease: 18 month longitudinal data from the IMAGE-HD study. Brain and Cognition. 83(1). 80–91. 49 indexed citations

15.

Tabrizi, Sarah J., Ralf Reilmann, Raymund A.C. Roos, et al.. (2011). Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. The Lancet Neurology. 11(1). 42–53. 408 indexed citations

16.

Vaccarino, Anthony L., Terrence Sills, Karen E. Anderson, et al.. (2011). Assessment of Depression, Anxiety and Apathy in Prodromal and Early Huntington Disease. PLoS Currents. 3. RRN1242–RRN1242. 11 indexed citations

17.

Vaccarino, Anthony L., Terrence Sills, Karen E. Anderson, et al.. (2011). Assessment of Motor Symptoms and Functional Impact in Prodromal and Early Huntington Disease. PLoS Currents. 2. RRN1244–RRN1244. 6 indexed citations

18.

Vaccarino, Anthony L., Karen E. Anderson, Beth Borowsky, et al.. (2011). An item response analysis of the motor and behavioral subscales of the unified Huntington's disease rating scale in huntington disease gene expansion carriers. Movement Disorders. 26(5). 877–884. 33 indexed citations

19.

Black, Mark D., Robert E. Featherstone, Yaw Senyah, et al.. (2010). AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. Psychopharmacology. 215(1). 149–163. 41 indexed citations

20.

Tabrizi, Sarah J., Douglas R. Langbehn, Blair R. Leavitt, et al.. (2009). Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. The Lancet Neurology. 8(9). 791–801. 756 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact